Zura Bio (NASDAQ:ZURA) Upgraded by Wall Street Zen to Sell Rating

Wall Street Zen upgraded shares of Zura Bio (NASDAQ:ZURA) from a strong sell rating to a sell rating in a report released on Saturday morning.

Other research analysts also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a report on Monday, July 6th. William Blair started coverage on Zura Bio in a report on Wednesday, July 8th. They issued an “outperform” rating for the company. Finally, Wedbush reiterated an “outperform” rating and issued a $15.00 price target on shares of Zura Bio in a research note on Wednesday, July 1st. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.75.

Zura Bio Trading Down 2.0%

Shares of ZURA stock opened at $5.43 on Friday. The firm has a fifty day moving average price of $4.67 and a 200 day moving average price of $5.38. The company has a market cap of $515.20 million, a P/E ratio of -4.98 and a beta of -0.03. Zura Bio has a 12 month low of $1.35 and a 12 month high of $7.44.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). On average, equities analysts forecast that Zura Bio will post -0.76 EPS for the current year.

Institutional Investors Weigh In On Zura Bio

Several large investors have recently modified their holdings of ZURA. Allworth Financial LP purchased a new position in shares of Zura Bio during the fourth quarter worth approximately $30,000. Scientech Research LLC purchased a new stake in Zura Bio in the 3rd quarter valued at $45,000. Dimensional Fund Advisors LP acquired a new stake in Zura Bio during the 4th quarter worth $123,000. Squarepoint Ops LLC acquired a new stake in Zura Bio during the 3rd quarter worth $109,000. Finally, Qube Research & Technologies Ltd purchased a new position in Zura Bio during the 3rd quarter worth $138,000. 61.14% of the stock is owned by institutional investors and hedge funds.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.